|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FMC1 |
Gene summary for FMC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FMC1 | Gene ID | 154791 |
| Gene name | formation of mitochondrial complex V assembly factor 1 homolog | |
| Gene Alias | C7orf55 | |
| Cytomap | 7q34 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q96HJ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 154791 | FMC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.51e-03 | 1.18e-01 | 0.0155 |
| 154791 | FMC1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.86e-06 | 2.32e-01 | -0.0811 |
| 154791 | FMC1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.84e-03 | 1.38e-01 | -0.1088 |
| 154791 | FMC1 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.65e-09 | 2.14e-01 | -0.1954 |
| 154791 | FMC1 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.61e-03 | 2.94e-01 | -0.2602 |
| 154791 | FMC1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.08e-06 | 3.67e-01 | -0.2196 |
| 154791 | FMC1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.26e-04 | 1.80e-01 | -0.1207 |
| 154791 | FMC1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.79e-04 | 2.04e-01 | -0.1526 |
| 154791 | FMC1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.10e-17 | 3.05e-01 | -0.1464 |
| 154791 | FMC1 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.25e-05 | 1.31e-01 | -0.1001 |
| 154791 | FMC1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.86e-09 | 2.19e-01 | -0.059 |
| 154791 | FMC1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.56e-06 | 2.60e-01 | -0.0842 |
| 154791 | FMC1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.96e-03 | 2.70e-01 | -0.0179 |
| 154791 | FMC1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.43e-19 | 3.76e-01 | 0.096 |
| 154791 | FMC1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.52e-14 | 5.10e-01 | 0.0528 |
| 154791 | FMC1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.22e-10 | 4.99e-01 | 0.0131 |
| 154791 | FMC1 | HTA11_10623_2000001011 | Human | Colorectum | AD | 4.46e-06 | 2.81e-01 | -0.0177 |
| 154791 | FMC1 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.21e-02 | 2.69e-01 | 0.0171 |
| 154791 | FMC1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.13e-08 | 2.39e-01 | 0.0338 |
| 154791 | FMC1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.75e-18 | 3.95e-01 | 0.0674 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
| GO:0050673 | Colorectum | AD | epithelial cell proliferation | 119/3918 | 437/18723 | 8.75e-04 | 8.51e-03 | 119 |
| GO:00098951 | Colorectum | SER | negative regulation of catabolic process | 84/2897 | 320/18723 | 3.93e-07 | 2.06e-05 | 84 |
| GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
| GO:000989520 | Esophagus | HGIN | negative regulation of catabolic process | 87/2587 | 320/18723 | 1.74e-10 | 1.68e-08 | 87 |
| GO:0009895111 | Esophagus | ESCC | negative regulation of catabolic process | 201/8552 | 320/18723 | 3.88e-10 | 1.05e-08 | 201 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00700711 | Esophagus | ESCC | proton-transporting two-sector ATPase complex assembly | 12/8552 | 15/18723 | 7.31e-03 | 2.63e-02 | 12 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
| GO:00443423 | Esophagus | ESCC | type B pancreatic cell proliferation | 15/8552 | 21/18723 | 1.54e-02 | 4.96e-02 | 15 |
| GO:000989522 | Liver | HCC | negative regulation of catabolic process | 196/7958 | 320/18723 | 7.98e-12 | 3.35e-10 | 196 |
| GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
| GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
| GO:0070071 | Liver | HCC | proton-transporting two-sector ATPase complex assembly | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
| GO:000989528 | Thyroid | HT | negative regulation of catabolic process | 50/1272 | 320/18723 | 2.72e-08 | 2.02e-06 | 50 |
| GO:005067320 | Thyroid | HT | epithelial cell proliferation | 48/1272 | 437/18723 | 6.86e-04 | 7.77e-03 | 48 |
| GO:005067820 | Thyroid | HT | regulation of epithelial cell proliferation | 43/1272 | 381/18723 | 7.38e-04 | 8.23e-03 | 43 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FMC1 | SNV | Missense_Mutation | novel | c.35G>C | p.Arg12Pro | p.R12P | Q96HJ9 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FMC1 | deletion | Frame_Shift_Del | novel | c.294delN | p.Gly99ValfsTer27 | p.G99Vfs*27 | Q96HJ9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FMC1 | SNV | Missense_Mutation | c.203N>A | p.Cys68Tyr | p.C68Y | Q96HJ9 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FMC1 | SNV | Missense_Mutation | novel | c.82C>T | p.Pro28Ser | p.P28S | Q96HJ9 | protein_coding | tolerated(0.87) | benign(0.015) | TCGA-EY-A1GX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FMC1 | SNV | Missense_Mutation | c.61N>G | p.Leu21Val | p.L21V | Q96HJ9 | protein_coding | tolerated(1) | benign(0) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FMC1 | SNV | Missense_Mutation | c.178N>T | p.His60Tyr | p.H60Y | Q96HJ9 | protein_coding | tolerated(0.25) | possibly_damaging(0.548) | TCGA-46-3768-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |